phase 3_completion
saveCellCarta Biosciences Inc — elranatamab (Phase III Trial Completion)
community read0 votes
Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Refractory Multiple Myeloma, Relapsed Multiple Myeloma
comments(0)
5-min edit window · permanent after that